AKTX Akari Therapeutics Plc

4.50
-1.90  -30%
Previous Close 6.40
Open 4.85
Price To book 2.32
Market Cap 52996199
Shares 11,776,933
Volume 1,964,446
Short Ratio 0.19
Av. Daily Volume 465,497

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data released April 24, 2017. Further update due at ASH December 9-12, 2017. Phase 3 program to commence 1Q 2018.
Coversin
Paroxysmal nocturnal hemoglobinuria (PNH)

Latest News

  1. Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
  2. Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares
  3. Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)
  4. Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics
  5. Akari Therapeutics Announces Further Clinical Progress
  6. Akari Therapeutics Rally Continues As William Blair Upgrades
  7. Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day
  8. Today's Research Reports on Stocks to Watch: Akari Therapeutics and Intercept Pharmaceuticals
  9. Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why
  10. Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
  11. Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
  12. Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%
  13. NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%
  14. Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher
  15. Akari Therapeutics Announces Appointment of David Horn Solomon as CEO
  16. Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
  17. FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017